SCHEDULE 13G/A: PFM Health Sciences Group Reports Zero Beneficial Ownership in ESSA Pharma Inc.

Sentiment:

Beneficial Ownership Report 14 February 2025 9:06 PM

PFM Health Sciences and its affiliates have reported that they no longer beneficially own any common shares of ESSA Pharma Inc., holding 0% of the outstanding class as of December 31, 2024.

Worse than expectedPFM Health Sciences, a significant institutional investor, has reduced its beneficial ownership in ESSA Pharma Inc. to 0% from a previously held stake (implied by Amendment No. 4), indicating a complete divestment of their position.

Summary

PFM Health Sciences, LP, PFM Health Sciences GP, LLC, Partner Asset Management, LLC, and Brian D. Grossman (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G.
As of December 31, 2024, the Reporting Persons collectively beneficially own 0 common shares of ESSA Pharma Inc.
This ownership represents 0% of the outstanding common shares of ESSA Pharma Inc.
The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, which is standard for a Schedule 13G filing.

Sentiment

Score: 3

Explanation: The document reports a complete divestment of shares by a significant institutional investor group, which is generally perceived as a negative signal for the company's stock, although no reasons for the divestment are provided within the filing itself.

Future Outlook

Industry Context

This filing is a routine disclosure of a change in beneficial ownership by an institutional investor group. It does not provide specific insights into broader industry trends for the pharmaceutical sector or ESSA Pharma's competitive landscape, beyond indicating a complete divestment by this specific investment group.

Stakeholder Impact

Shareholders: The complete divestment by PFM Health Sciences and its affiliates could be interpreted negatively by other shareholders, potentially leading to a decrease in investor confidence or share price, although the filing itself provides no rationale for the divestment.

Key Dates

Date	Description
02/01/2024	Date of the power of attorney for Brian Grossman, referenced in the signature section.
12/31/2024	Date of event which requires filing of this statement, indicating the point at which beneficial ownership became 0%.
02/14/2025	Date the Schedule 13G/A Amendment No. 4 was signed and filed.

Recommendation

sell

Keywords

ESSA Pharma Inc., PFM Health Sciences, Schedule 13G, Beneficial Ownership, Common Shares, Institutional Investor, SEC Filing, Ownership Change

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.